Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25417355 | 0.77 | NPC1 (0.38) | PDE4BNPC1RAB9A | |
| SCHEMBL28445687 | 0.73 | PDE4B (0.38) | PDE4BPDE3A | |
| SCHEMBL21584712 | 0.69 | NPC1 (0.36) | NPC1RAB9A | |
| SCHEMBL29723754 | 0.68 | AHR (0.36) | — | |
| SCHEMBL15807120 | 0.66 | PIK3CG (0.58) | NPC1RAB9A | |
| SCHEMBL21584715 | 0.65 | GAA (0.35) | — | |
| SCHEMBL24529390 | 0.64 | NPC1 (0.33) | NPC1RAB9A | |
| SCHEMBL21584829 | 0.63 | PIK3CG (0.39) | NPC1RAB9A | |
| SCHEMBL21584702 | 0.63 | — | — | |
| SCHEMBL21584826 | 0.63 | NPC1 (0.40) | PDE4BPDE3ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111801328-B | Autotaxin inhibitors and uses thereof | 四川海思科制药有限公司 | 2023-06-02 | — | — | CN | disclosed |
| US-11040972-B2 | Autotaxin inhibitors and uses thereof | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2021-06-22 | — | — | US | disclosed |
| US-20200354357-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2020-11-12 | — | — | US | disclosed |
| CN-111801328-A | Autotaxin inhibitors and uses thereof | 弗朗塞拉美国制药有限责任公司 | 2020-10-20 | — | — | CN | disclosed |
| US-10711000-B2 | Autotaxin inhibitors and uses thereof | FRONTHERA U.S. PHARMACEUTICALS LLC (US) | 2020-07-14 | — | — | US | disclosed |
| WO-2019228403-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | FRONTHERA U.S. PHARMACEUTICALS LLC (US) | 2019-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10711000-B2 | Autotaxin inhibitors and uses thereof | ENPP2, SERPINB1, RNASE1 | PDE4B 2208/4885PDE3A 2448/4885NPC1 2850/4885 |
| US-11040972-B2 | Autotaxin inhibitors and uses thereof | ENPP2, SERPINB1, RNASE1 | PDE4B 2208/4885PDE3A 2448/4885NPC1 2850/4885 |
| US-20200354357-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | ENPP2, SERPINB1, RNASE1 | PDE4B 2208/4885PDE3A 2448/4885NPC1 2850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.